# A Phase I/II Open Label Single Centre Trial to Assess the Safety, Tolerability and Efficacy of Single Dose Neoadjuvant Anti-CLEVER-1 Antibody Bexmarilimab in Localised Renal Cell and Colon Carcinoma

> **NCT05104905** · PHASE1,PHASE2 · WITHDRAWN · sponsor: **Faron Pharmaceuticals Ltd**

## Conditions studied

- Carcinoma, Renal Cell
- Carcinoma Colon

## Interventions

- **DRUG:** bexmarilimab

## Key facts

- **NCT ID:** NCT05104905
- **Lead sponsor:** Faron Pharmaceuticals Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2021-10-07
- **Primary completion:** 2022-01-28
- **Final completion:** 2022-01-28
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Since no patients have been enrolled in RENACOL, and safety and tolerability data is rapidly accumulating in another ongoing study, sponsor considered that RENACOL study is no longer needed to assess the safety profile of bexmarilimab
- **Last updated:** 2022-05-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05104905

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05104905, "A Phase I/II Open Label Single Centre Trial to Assess the Safety, Tolerability and Efficacy of Single Dose Neoadjuvant Anti-CLEVER-1 Antibody Bexmarilimab in Localised Renal Cell and Colon Carcinoma". Retrieved via AI Analytics 2026-06-22 from https://api.ai-analytics.org/clinical/NCT05104905. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*